Moderna to cut mRNA drug substance production at Lonza facility

(Reuters) - Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand.

The U.S. company had announced last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production.

Moderna expects to absorb the demand currently supported by Lonza at its internal manufacturing site at Norwood in Massachusetts for 2024-25, the company said.

(This story has been corrected to say the facility belongs to Lonza, not Moderna, in the headline and copy)

(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)